BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, November 7, 2011
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
11/4
cls
|
|
Active
Biotech AB (SSE:ACTI)
|
Jefferies
|
Peter
Welford
|
Downgrade
|
Hold
(from buy)
|
-34%
|
SEK19.40
|
|
Welford
also lowered his target to SEK20 from SEK100 after partner Teva
Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it would be "premature"
to submit an NDA at this time for laquinimod to treat relapsing-remitting
multiple sclerosis (RRMS) (see B10). Teva, which said it will work
with FDA to design an additional trial for the quinoline-3-carboxamide
immunomodulator, had planned to submit an NDA early next year. In August,
laquinimod missed the primary endpoint in the Phase III BRAVO trial to treat
RRMS (see BioCentury, Aug. 8).
|
|
Cardiome
Pharma Corp. (TSX:COM; NASDAQ:CRME)
|
Bloom
Burton
|
Philippa
Flint
|
Downgrade
|
Sell
(from hold)
|
-22%
|
$2.77
|
|
Flint
also lowered her target to $3.50 from $6 on news that partner Merck &
Co. Inc. (NYSE:MRK) will perform another Phase I trial of oral
vernakalant to treat atrial fibrillation and start Phase II in late 2012.
Merck markets an IV formulation of the mixed ion channel antagonist in Europe
under the name Brinavesse.
|
|
Charles
River Laboratories International Inc.
(NYSE:CRL)
|
Leerink
|
John
Sullivan
|
Price
target
|
Market
perform
|
-14%
|
$28.99
|
|
Sullivan
lowered his target to $32-$34 from $37-$39, saying the tool supplier "continues
to face headwinds" in its preclinical services (PCS) business. Charles
River reported a 9% decline in 3Q11 PCS revenue, which Sullivan attributed to
continued "soft demand" from large pharma clients and bookings
heavily weighted towards short-term and less complex studies. Sullivan also
noted the company plans to reduce headcount by about 2% this quarter, mainly
in the PCS segment. He estimates an annual cost savings of about $7.5M (see
"EPS Watch," A17).
|
276
words displayed of
1020
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]